Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients.
Fang FangXiao-Xi LanRong-Hua HuWu-Han HuiHong ZhaoYi-Xian GuoBing-Xin JiHong-Jun LiuLi SuWan-Ling SunPublished in: Therapeutic advances in neurological disorders (2024)
Bortezomib was well-tolerated by patients with POEMS syndrome. Compared with CD ± T regimen, BCD as the induction regimen achieved better VEGF response and earlier hematological remission. Autologous stem cell transplantation used as consolidation therapy further improved the neurological and hematological remission rates, resulting in better OS and PFS.
Keyphrases
- newly diagnosed
- stem cell transplantation
- high dose
- low dose
- end stage renal disease
- multiple myeloma
- disease activity
- case report
- ejection fraction
- chronic kidney disease
- ulcerative colitis
- cell therapy
- endothelial cells
- bone marrow
- peritoneal dialysis
- rheumatoid arthritis
- blood brain barrier
- mesenchymal stem cells
- smoking cessation